Kim Chris's Form 4 filing
Liminatus Pharma, Inc. (LIMN) · filed Jul 14, 2026
- Accession no.
- 0001104659-26-083588
- Filed
- Jul 14, 2026, 5:46 PM ET
- Trade date
- Jul 2, 2026
- Filing delay
- 12 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. It was filed 12 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kim ChrisCIK 0001972385 | Director, Officer (Chief Executive Officer), 10% Owner |
| Valetudo Therapeutics LLCCIK 0002067359 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Common Stock, par value $0.0001 per share | JOtherAcquired | +3,448,926 | – | – | 5,244,351 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.